Bispecific Antibodies

#Antibodies #Bispecific Antibodies #FDA #Monoclonal antibodies #Neuroscience #Oncology

This week in drug discovery (4-8 March) 

News round-up for 4-8 March by DDW Digital Content Editor Diana Spencer. It was antibodies hitting the headlines this week, with the discovery of antibodies with potential against a new influenza target, the launch of a Phase I trial to investigate a novel type of bispecific antibody, and… Read More

#News

Woman reaches for inhaler
#Asthma #Bispecific Antibodies #Innovent #Phase I trial

Humanised bispecific antibody for asthma enters Phase I trial

Biopharmaceutical company Innovent Biologics has launched the first-in-human (FIH) Phase I clinical trial of IBI3002, a novel bispecific antibody targeting Interleukin 4 receptor α (IL-4Rα) and thymic stromal lymphopoietin (TSLP). The study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of IBI3002 in healthy participants and… Read More

#News

#Bispecific Antibodies #Blood cancer #Cancer research #CAR-T #JAK inhibitor #Oncology

This week in drug discovery (29 January – 2 February) 

News round-up for 29 January – 2 February by DDW Digital Content Editor Diana Spencer. Sunday 4 February is World Cancer Day, an international awareness day led by the Union for International Cancer Control (UICC), so the round-up this week will focus on oncology, including the UK approval of… Read More

#News

#Bispecific Antibodies #Cancer treatment #Checkpoint inhibitor therapies #Clinical trials #Solid tumours

Phase I trial for first-in-class bispecific antibody for cancer

Onward Therapeutics has announced the Phase I clinical trial of OT-A201, a first-in-class bispecific antibody targeting two immune checkpoints is in progress.  The study aims to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary anti-tumoural activity of OT-A201.   The study is a European multicentre and… Read More

#Cancer Research #News

Follicular lymphoma
#AbbVie #Bispecific Antibodies #Clinical trials #Follicular lymphoma #Genmab

New data for relapsed/refractory follicular lymphoma treatment 

Genmab and AbbVie have announced updated data presented at ASH from the companies’ ongoing Phase I/II EPCORE NHL-1 clinical trial investigating epcoritamab (DuoBody CD3xCD20).   Epcoritamab is a T-cell engaging bispecific antibody administered subcutaneously in 128 adult patients with relapsed, progressive or refractory CD20+ mature B-cell non-Hodgkin’s lymphoma… Read More

#News

Natural killer cells
#Bispecific Antibodies #Cell therapy #Collaboration #NAYA Biosciences #Oncology #ONK Therapeutics

Partners explore NK cell therapy and bispecific antibodies combo

ONK Therapeutics and NAYA Biosciences have agreed to develop a combination therapy of ONK’s optimally-engineered natural killer (NK) cell therapies and NAYA’s FLEX-NK bispecific antibodies. The partnership will explore the combination of ONK’s ONKT105, CISH + TGFβR2 double knock-out (KO), sIL-15 knock-in (KI) allogeneic NK cell… Read More

#Business & Investment #Cancer Research #News

Lisbon skyline
#Bispecific Antibodies #Immunotherapy #Machine learning #PEGS Europe 2023 #Protein engineering

What to expect from PEGS Europe 2023: Day 3

Ahead of protein and antibody engineering conference PEGS Europe 2023 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. On Day 3, Thursday 16 November 2023, the tracks include: the second part of machine learning for protein engineering, antibodies against… Read More

#Exclusive Content

Lisbon skyline
#Antibodies #Antibody drug conjugate (ADC) #Biochemistry #Biologics #Biologics / Biotechnology #Bispecific Antibodies #Combination therapy #Engineered antibodies #PEGS Europe 2023

What to expect from PEGS Europe 2023: Day 1

Ahead of protein and antibody engineering conference PEGS Europe 2023 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. On Day 1, Tuesday 14 November 2023, the tracks include: Display of biologics, antibody-based cancer therapies, safety and efficacy of bispecific… Read More

#Exclusive Content

Blood cancer
#Bispecific Antibodies #Cancer research #Haematology #MHRA #Oncology #UK

New UK therapy option for hard-to-treat lymphoma

The MHRA has granted conditional marketing authorisation for Tepkinly (epcoritamab) as a bispecific treatment for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The conditional marketing authorisation for Great Britain is based on the single-arm Phase… Read More

#News #Regulatory

European Commission
#Bispecific Antibodies #EU #European Commission #Janssen #Myeloma #Oncology

“Important new approach” to myeloma now available in the EU

The European Commission (EC) has granted conditional marketing authorisation (CMA) for Janssen’s Talvey (talquetamab) as monotherapy for relapsed and refractory multiple myeloma (RRMM). It is approved in adult patients who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an… Read More

#News #Regulatory

Multiple myeloma
#Accelerated assessment #Bispecific Antibodies #FDA #Immunotherapy #Myeloma #Pfizer #Phase II trial

FDA accelerates approval for multiple myeloma immunotherapy

The US Food and Drug Administration (FDA) has granted accelerated approval to Pfizer’s Elrexfio (elranatamab-bcmm) for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM). The drug is approved in patients who have received at least four prior lines of therapy, including a… Read More

#News #Regulatory

FDA
#Bispecific Antibodies #FDA #Janssen #Myeloma #Oncology

Janssen myeloma drug approved in US via a restricted programme

The FDA has granted accelerated approval to Janssen’s talquetamab-tgvs (Talvey) for adults with relapsed or refractory multiple myeloma. It has been approved in patients who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. Read More

#News #Regulatory

#Antibodies #Bispecific Antibodies #Cancer research #CHMP #Oncology

DDW Highlights: 7 August 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The pace of innovation in cancer drug discovery showed no signs of slowing… Read More

#News

#Antibodies #Bispecific Antibodies #Cancer research #CHMP #Oncology

This week in drug discovery (31 July – 4 August)  

News round-up for 31 July – 4 August by DDW Digital Content Editor Diana Spencer. The pace of innovation in cancer drug discovery showed no signs of slowing this week, with several pretty momentous discoveries boosting research in the sector. These include the creation of a… Read More

#News

#Antibodies #Bispecific Antibodies #Cancer research #CHMP #Oncology

New podcast episode: DDW Highlights 31 July 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  To coincide with the publication of the DDW eBook ‘Antibody discovery:… Read More

#News

#Antibodies #Bispecific Antibodies #Cancer research #CHMP #Oncology

This week in drug discovery (24-28 July)  

News round-up for 24-28 July by DDW Digital Content Editor Diana Spencer. To coincide with the publication of the DDW eBook ‘Antibody discovery: Breakthroughs accelerating therapeutic antibodies’, our news highlights this week all focus on antibodies, particularly the recommendation by the EU’s CHMP… Read More

#News